Coughlin changes hats at hearing on drug pricing

Pharmaceutical pricing legislation picking up steam

AT A PACKED STATE HOUSE hearing Thursday on legislation to rein in the cost of pharmaceuticals, MassBIO CEO Robert Coughlin and two of his national colleagues were pitching the same argument they’ve been using for a long time – that any form of price control would jeopardize a thriving local industry and hinder the development(...)

Read More »